Alphagalileo > Item Display
en-GBde-DEes-ESfr-FR

The brain’s powerhouses are damaged in Creutzfeldt-Jacob disease


Mitochondrial failure contributes to Creutzfeldt-Jacob disease, study suggests.

A study performed by researchers from the University of Bergen, Norway, and the University of Vienna, Austria, shows damage of the mitochondria –the cell’s microscopic powerhouses – in the brain of people with Creutzfeldt-Jacob disease.

The researchers found that the mitochondrial power generator (known as the respiratory chain) is severely impaired in brain cells from people who died with Creutzfeldt-Jacob disease.

“These mitochondrial defects were widespread in the brain and correlated with the severity of disease,” says Professor Charalampos Tzoulis at the University of Bergen and Haukeland University Hospital, Bergen.

Suggests contribution to disease
Damaged mitochondria will no longer be able to provide the energy required for neuronal maintenance and function.

“These findings strongly suggest that mitochondrial failure contributes to the pathogenesis of Creutzfeldt-Jacob disease,” says Tzoulis.

Hoping for new treatment
Tzoulis highlight the need to better understand how mitochondrial failure contributes to Creutzfeldt-Jacob disease.

“We hope that this study may be exploited towards developing treatments for this incurable and deadly condition,” says Charalampos Tzoulis.

Facts:Creutzfeldt-Jacob disease

  • Creutzfeldt-Jacob disease is a rare and rapid progressive and severe disease that cause loss of brain tissue.
  • Creutzfeldt-Jacob disease is a lethal brain disease that annually affects 1-2 people per million population, and causes death within 4-24 months.
  • The disease normally affects individuals above the age of 60, and causes a combination of invaliding symptoms, often dementia and movement disorders.
  • In spite of years of research, there is currently no cure.
Acta Neuropathologica Communications volume 8, Article number: 50 (2020)
Mitochondrial respiratory chain deficiency correlates with the severity of neuropathology in sporadic Creutzfeldt-Jakob disease
Irene H. Flønes, Gerda Ricken, Sigrid Klotz, Alexandra Lang, Thomas Ströbel, Christian Dölle, Gabor G. Kovacs & Charalampos Tzoulis
https://doi.org/10.1186/s40478-020-00915-8
Attached files
  • Charlampos "Haris" Tzoulis with groundbreaking research on Creutzfeldt-Jacob disease, Photo: Ingvild Festervoll Melien.
Regions: Europe, Norway, Austria
Keywords: Health, Medical

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
Copyright 2021 by DNN Corp Terms Of Use Privacy Statement